FARXIGA approved in the US for the treatment of pediatric type-2 diabetes

US patients aged 10 years and older can now benefit from FARXIGA for type-2 diabetes


Approval based on results from T2NOW, one of the largest pediatric type-2 diabetes Phase III trials to date

...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Germany ,United States ,China , ,National Institute Of Diabetes ,International Diabetes Federation ,Astrazeneca ,Drug Administration ,Us Centers For Disease ,National Diabetes Statistics ,European Medicines Agency ,Centers For Disease ,Executive Vice President ,Biopharmaceuticals Business Unit ,Disease Control ,New England Journal ,Medicine Evidence ,Mycotic Infections ,Common Adverse Reactions ,Prescribing Information ,Rare Diseases ,Pediatric Type ,Diabetes Federation ,Atlas Tenth Edition ,Kidney Diseases ,Res Clin ,Aged Diabetes ,Clin Endocrinol ,Risk Factors ,Diabetic Peripheral Neuropathy ,Youth With Type ,Tissue Insulin Resistance ,Spectrum From Normal Weight ,From Normal Glucose Tolerance ,Impaired Glucose Tolerance ,Restoring Insulin Secretion ,Nordisk Pediatric Type ,Global Expert ,Medicines Agency ,Evaluate Safety ,Patients With Type ,Mellitus Aged ,Diabetes Metab Res ,Subanalysis From ,Global Burden ,Disease Study ,Report Card ,